Stockholm Uppsala Europe s creative life science hub

Transcription

1 Stockholm Uppsala Europe s creative life science hub Life Science Day 9th Swiss-Scandinavian Bio-Business Seminar Feb 5th Zürich

2 Stockholm Business Region Development AB The official investment promotion agency of Stockholm Mission: Attracting investments to the Stockholm-Uppsala region - Establishments - Industrial co-operations - VC

3 A great place to live! 3rd best city to live in globally by the Economist Intelligence Unit in Toronto 2. Montreal 3. Stockholm 4. Amsterdam 5. San Francisco 6. Melbourne 7. Zurich 8. Washington, DC 9. Sydney 10. Chicago Sourcw:

4 A safe place to live 4th safest city to live in globally by the Economist Intelligence Unit in Tokyo 2. Singapore 3. Osaka 4. Stockholm 5. Amsterdam 6. Sydney 7. Zurich 8. Toronto 9. Melbourne 10. New York City 50 cities were ranked on: Digital security Health Security Infrastructure Personal safety Source:

5 Recently Stockholm has received much attention as a successful Start up Scen. This is also the case in London and Berlin - But in Stockholm some of the companies have kicked of and become Billion dollar companies. "Stockholm is Europe's start-up superstar The New York Times (2013) "Stockholm is the home to some of the continent s most impressive tech start-ups of recent years Financial Times (2014) "Sweden offers an extremely competitive, largely corruption-free economy with access to new products, technologies, skills, and innovations U.S. Department of State (2013) "Stockholm is one of Europe's most vibrant, and underrated, digital scenes" The Guardian (2013)

6 Areas of excellence: Oncology Neuroscience Metabolic diseases Regenerative medicine Cardiovascular disease Infectious disease, Inflammation & Immunology Digital health

7 Strong and established ICT, life science & healthcare sectors Stockholm/Uppsala region with organizations that can drive digital health forward Renowned healthcare institutions Healthcare Leading ICT companies headquartered/r&d active ICT DH Life science Strong presence of globally leading pharma/med tech DH ecosystem participants

8

9

10 Companies Oncology: Affibody Biovica International ModPro AB NeoDynamics NoseLabs AB Oss-Design AB SCIBASE AB Spiber Technologies AB XSpray Digital health: Biosync Tech AB DD Innovation AB Hoa s Tool Shop AB Inerventions AB Mando Group AB MID AB One Lab Quick Posture Sw. AB SciLife Clinic AB Neuro: AlzeCure BioChromix AB Glucox Biotech AB Infectious Diseases, Inflammation & Immunology: Abera Bioscience Affibody Athera Biotech. AB Diamyd Medical AB(publ) Episurf Medical (publ) Glucox Biotech AB IsletOne Therapeutics ModPro AB Q-linea AB Scandinavian Biopharma Swecure AB Viscogel AB Metabolic Diseases: Diamyd Medical AB(publ) Glucox Biotech AB Mando Group AB Other: BioLamina AB Bio-Works Tech. AB CathPrint AB Corline Systems AB Dilafor AB Gradientech AB MID AB OssDsign AB Premune SensAbues AB Senzime AB Spiber Technologies AB Sportglass AB SymCel Sverige AB Xbrane Bioscience

11 Challenge Mental illness is the number one contributor to disease burden worldwide - more than cancer or cardiovascular disease. Er logga här Our solution Using our digital service - an easy to implement professional system, which consist of a mobile app for the client and a web app for the therapist - psychological treatment can be twice as efficient as it is today. This has been proven in a large RCT at Linköping University. Market Potential Costs for outpatient treatment of depression is $12.5 billion annually only in the U.S. Early development Company name: Category : Sub category: Location : Hoa s Tool Shop AB E-health Clinical psychology Stockholm Proof of concept CE-marking Commercialised

12 CHALLENGE Psychological disorders, such as depression, are major health problems, which lowers the quality of life for individuals and generates enormous costs for society. Mental illness cost more than $80 billion every year, only in the US. Even if psychological treatment has a success rate of 70 % for depression and anxiety treatment, only one third of patients get professional help by a therapist. More cost- and time effective treatment formats must be developed to meet the demands. BUSINESS MODEL Our service is easy to implement and therefore we can sell our service as a subscription model directly on the internet and skip complicated implementation processes. We will charge a monthly fee per active therapist using the service. Also, we will charge the end-users (patients) after the treatment is over, since the app can be used as a relapse prevention tool. Our tool has been sold in Sweden in a non-clinical context. We have had paying customers that have stayed with us for over two years. SOLUTION Our mission is to make psychotherapy so effective that everybody in need can get help. Using our digital service - an easy to implement professional system, which consist of a mobile app for the client and a web app for the therapist - psychological treatment can be twice as efficient as it is today. This means that waiting lists can be cut, healthcare companies can be more profitable and that patients can get healthier faster. Already proven in a large scientific study that showed that our service, together with four face-to-face sessions with a therapist is as effective as traditional CBT treatment including ten face-toface sessions. Our starting point is depression treatment, but the vision is that our digital service becomes a platform for all types of psychotherapy. MARKET Estimated cost of depression alone is $160 million per 1 million inhabitants in high-income countries. Costs for outpatient treatment of depression is $12.5 billion annually in the U.S. Moreover, during a one-year period, anxiety disorders will affect 14% of the population and depression will affect 6%. About 8.7 million people in the U.S. receive treatment for depression each year. In the U.S. there are approximately 600,000 mental health professionals. If we reach a 20 % market penetration and charge our service $100/professional/month, we will have an annual revenue of $144 M.

13 PROGRESS Development We have a working product that has been proven to work in a large clinical study. The study included 26 therapists at three clinics in Stockholm and Linköping. The study showed that our service, together with four face-to-face sessions is as effective as traditional CBT treatment including ten face-to-face sessions. The study will be published in a large psychiatric journal later this year. Next steps Our next step is to bring proof of concept to the tool on the open market. During Q1 and Q we will establish beta customers and try the tool on the market in Sweden. Also, we are looking to expand in the U.S. during Q2 with beta testing. Cigna, one of the largest insurance companies in the U.S. has shown great interest in our solution. OTHER INFORMATION Our product has been up and running since 2011 and sold to professionals in a non-clinical context and used for leadership coaching. However, with the latest clinical study that was finished May 2013, a clinical approach has been established. The company is tightly connected to Linköpings University and one of the most leading professors within the field of digitally distributed psychological treatment. Three studies have already been published on our tool and more studies are about to be published. Financials (SEK) Revenue EBIT Balance sheet total 605 T SEK -172 T SEK Five Valuation Largest Owners - Shares - (%) - Hoa Ly 39 John Airaksinen 32 Niklas Laninge 13 Albert Örwall 6 Jonas Jendi 6 Other 106 T SEK 532 T SEK 41 T SEK 283 T SEK Founded 2011 Employees (FTE) 4 How much funding in total has been raised in previous rounds?

14 TRACK RECORD AND EXPERTISE BOARD OF DIRECTORS AND MANAGEMENT After founding Hoa's Tool Shop in February 2011, the company was named one of Europe s most promising startups by Wired Magazine, listed as one of Sweden s top 25 web entrepreneurial companies by Internetworld and selected as one of nine young innovative Swedish companies to receive the Vinnova Vinn-Nu grant of In addition, Hoa's Tool Shop s app was shortlisted for a Swedish Golden Mobile Award. In 2013, the magazine Veckans Affärer, named Hoa s Tool Shop as as one of the most promising startups in Sweden. Our team has a unique combination of tech and design skills, business experience, research skills and deep knowledge of behavioral science. No pure tech team, nor any team with only psychologists would be able to provide a service like this. The company is headed by Hoa Ly (CEO), psychologist and researcher on digitally distributed therapy at Linköpings University. Hoa is doing research with the most prosperous scientists in the world within this field, including professor Gerhard Andersson and professor Pim Cuijpers. Hoa s research has been acknowledged in many parts of the world after a TEDx-talk and presentations at conferences. WHAT ARE WE LOOKING FOR? Hoa Ly John Airaksinen Niklas Laninge Albert Örwall Jonas Jendi CEO & co-founder Product manager & co-founder Community manager & co-founder Developer & co-founder Chairman & co-founder Hoa's Tool Shop is a privately held company with paying customers and small running costs. The company is interested in finding active financial investors with a view of taking the company to an international market. During Q3 2014, Hoa's Tool Shop is looking to expand the team with tech competence and sales staff to be able to go on to a commercializing phase. We are looking for an investment in the range of 500 k k, which would give us a runway of months with six employees. Contact information Hoa Ly, CEO hoa@hoastoolshop.com +46 (0)

15 Criteria Impact / solve real problems Innovation Height Good management, trustworthy and suitable for the task Relatively mature, but may still be in development Strong intention to seek contact with investors, partners and to expand Academic engagement / interaction Have funds to match grant funding Being situated in the Stockholm / Uppsala region Looking for partners in industry Looking for investment of approx. SEK 5-50 million

16 Achivements Life Sciences, investments Approx 200 opportunities 13 visits of foreign journalists Anchored partners to continously receive high quality companies to Hotlist

17 Challenge Pathogens such as HIV, malaria and TB are too clever and complex for normal simple vaccines Vaccines need to be more sophisticated Our solution Abera has developed a universal platform that is more efficient, safe and has lower production time and cost compared to conventional vaccine technologies Vaccine candidates in pre-clinical phase: Streptococcus Pneumoniae and Tuberculosis Vaccine candidates in discovery phase: Chlamydia and Therapeutic Cancer B IO S C IEN C E Market Potential The WHO estimates that the vaccine market will be worth 100 BUSD by 2025 The vaccine market grows rapidly with a growth rate of 10-15% (compared to 5-7% for the global pharmaceutical market) Early development Company name: Category : Sub category: Location : Abera Bioscience Biotech Vaccine Development Stockholm Proof of concept Clinical phase Commercialised

18 Challenge Neurodegenerative diseases, e.g. Alzheimer s Disease (AD), are debilitating CNS conditions for which there is no curative or preventive treatment available. The field is hampered by limited disease understanding, difficulties to set appropriate diagnosis and inconclusive clinical trials. Our solution Identify and pursue drug targets that exhibit a clear linkage to well-defined patient populations. Combine technology and biology innovation to deliver efficacious therapies. Market Potential Approximately 115 million people are estimated to be suffering from AD in 2050, indicating a significant market potential for a novel disease modifying therapy. Early development Company name: Category : Sub category: Location : ALZECURE DRUG DEVELOPMENT NEURODEGENERATION STOCKHOLM Proof of concept CE-marking Commercialised

19 Challenge Need for better care of cardiovascular disease (CVD) patients Inflammation is not specifically addressed by current treatments Our solution PC-mAb to prevent complications in CVD CVDefine kit to identify patients that are most likely to benefit from treatment Market Potential CVD is the leading cause of death in the developed world Innovative Biopharmaceuticals for Cardiovascular Disease Treatment and Prevention Company name: Category : Sub category: Diagnostics Location : Athera Biotechnologies AB Drug development/biotech Therapeutic Antibodies/Companion Stockholm PC-mAb has first in class potential and targets the inflammatory component of CVD Discovery Preclinical development Clinical development Commercialized

20 Challenge How will the cancer disease develop? Will the patient respond to chemo-therapy? How do we know if a cancer treatment gives desired effect? Can we increase the development success rate of new cancer drugs? Our solution DiviTum has the ability to prognosticate cancer disease development DiviTum has the ability to predict patient response to therapy DiviTum can monitor the effect of a cancer treatment DiviTum can predict response and identify optimal patient cohorts, accelerating drug development Company name: Category : Sub category: Location : Biovica International Medtech Diagnostics Uppsala Market Potential 29 million people are living with cancer globally (5-year prevalence according to Globocan) Market potential estimated to >1,5 Billion $US globally Early development Proof of concept CE-marking Commercialized

21 Challenge What substances trigger our immune cells to move to the site of infection? What substances can counteract that cancer cells spread in the body? Our solution CellDirector can determine which substances that triggers immune cells or make cancer cells migrate CellDirector shortens the time for drug development Market Potential Cell based assays will be used earlier in the drug discovery process Microfluidic assays save time and costs with increased quality in results Early development Company name: Gradientech AB Proof of concept Category : BIOTECH CE-marking Sub category: CELL BASED ASSAYS Location : UPPSALA Commercialised

22 Challenge Spasticity causes pain and difficulties to move for people with e.g. CP and stroke Available treatments are expensive and associated with pain and heavy side effects Our solution A body suit system, Mollii, that reduces spasticity and increases patient activity and quality of life Cost-efficient and less side-effects compared to existing options for spasticity management Market Potential 3.5M patients in US and Western Europe On average EUR spent on spasticity management per patient per year in these countries Company name: Category : Sub category: Location : Inerventions AB Medtech Assistive Devices Stockholm Early development Proof of concept CE-marking Commercialised

23 SENZIME Senzime AB is a bio-tech company based in Uppsala, Sweden. The company develops and markets a unique and proprietary enzyme based biosensor technology with a wide applicability throughout different medical and bio/chemical processes and industries. Senzime focuses the following application areas: Biotechnology - Process control in the development and production of pharmaceuticals Health Care/Med Tech - Online monitoring Early development Company name: Category : Sub category: Location : Senzime AB Biotech/Med Tech Monitoring Devices/Hospital Equipment Uppsala Proof of concept Med Tech CE-marking Commercialised - Biotech

24 Challenge Rising prevalence of allergies No existing cure against allergy Our solution Our technology is directed towards stimulation of the immune system, which is required for proper activation of immunological tolerance and prevention of allergy Market Potential 11 million infants are born in the western world annually. 40 % of these infants develop allergy Early development Company name: Category: Sub category: Location: Swecure AB BIOTECH PHARMACEUTICALS, PROBIOTICS STOCKHOLM Proof of concept CE-marking Commercialised

25 Challenge There is a need for improved efficacy in modern vaccines Adjuvants play a significant role for improved vaccines, but few have the prerequisites to reach the market Our solution ViscoGel - proven safety and efficacy as vaccine adjuvant in Phase I/II clinical trial Regulatory uncomplicated proprietary technology with low COGS Market Potential Global vaccine market USD 28 bn (2010) New adjuvants are expected to be a major growth driver in the vaccine field. Early development Company name: Category : Sub category: Location : Viscogel AB Biotech Vaccine development and drug delivery Solna Proof of concept CE-marking Commercialised

26 Challenge Health professionals are still using analog methods for measuring movement. Lab testing is scarce & expensive Our solution Software using affordable off-the-shelf gaming sensor for 3D imaging Screening, analysis & user feedback Monitoring of progress over time Market Potential 1 in 3 people globally have movement disorders. Cost in USA = $565b/year 1 in 3 people over 65 fall each year. Cost in Sweden = 24.6b SEK/year 100m in EU have musculoskeletal chronic pain and 40% remain undiagnosed. Early development Company name: Category : Sub category: Location : Quick Posture Sweden AB DIGITAL HEALTH HEALTH SCREENING SOFTWARE STOCKHOLM Proof of concept CE-marking Commercialised

27 Thank you Thank you!